Complete pre-anesthesia evaluation including blood work, ECG, and knee MRI. Patient must maintain NPO status for at least 8 hours. Prophylactic antibiotics administered 60 minutes prior to incision. Informed consent obtained regarding long-term rehabilitation requirements.
Post-operative inpatient stay requires strict non-weight-bearing status for 6 weeks, followed by a graduated physical therapy program. DVT prophylaxis, pain management via multimodal analgesia, and knee bracing are mandatory. Discharge upon successful physical therapy assessment and stable wound healing.
Autologous Chondrocyte Implantation (ACI) for Knee Cartilage Restoration: A Comprehensive Clinical Guide
Autologous Chondrocyte Implantation (ACI) represents a landmark advancement in regenerative orthopedic surgery. Designed to treat symptomatic, full-thickness articular cartilage defects in the knee, ACI utilizes the patient’s own biological material to regenerate hyaline-like cartilage. Unlike palliative procedures that offer symptomatic relief, ACI is a cell-based restorative technique aimed at biological structural repair.
1. Introduction & Overview
Articular cartilage is characterized by a lack of vascularity, lymphatic drainage, and innervation, which renders it inherently incapable of intrinsic healing. Once damaged via trauma or osteochondritis dissecans, the tissue undergoes progressive degeneration. ACI was developed to address these focal defects by harvesting healthy chondrocytes, expanding them in a laboratory setting, and re-implanting them into the defect site to facilitate the synthesis of a robust extracellular matrix.
The Evolution of ACI
- First Generation: Periosteal-covered cell suspension.
- Second Generation: Collagen-covered cell suspension.
- Third Generation (MACI): Matrix-induced Autologous Chondrocyte Implantation, utilizing a porcine-derived collagen membrane pre-seeded with chondrocytes.
2. Technical Specifications & Mechanisms
The biological goal of ACI is the production of hyaline-like cartilage, which contains Type II collagen and proteoglycans, rather than the mechanically inferior fibrocartilage produced by marrow-stimulation techniques like microfracture.
The Two-Stage Biological Process
- Harvest Phase: Arthroscopic biopsy of healthy cartilage (typically from the intercondylar notch or superior ridge of the trochlea).
- Expansion Phase: Chondrocytes are isolated, enzymatically digested, and cultured in a GMP-certified laboratory for 4–6 weeks.
- Implantation Phase: The expanded cells (now a concentrated suspension or seeded on a scaffold) are implanted into the debrided defect site.
| Feature | Description |
|---|---|
| Cell Source | Autologous (patient-derived) |
| Primary Matrix | Type II Collagen / Proteoglycans |
| Expansion Time | 4–6 Weeks |
| Target Tissue | Hyaline-like articular cartilage |
3. Clinical Indications & Usage
ACI is not a first-line treatment for generalized osteoarthritis. It is indicated for symptomatic, focal, full-thickness defects in patients who have failed conservative management or previous surgical interventions.
Patient Selection Criteria
- Age: Typically 15–55 years.
- Defect Size: Ideal defects range from 2 cm² to 10 cm².
- Lesion Type: International Cartilage Regeneration & Joint Preservation Society (ICRS) Grade III or IV.
- Alignment: The patient must have a stable, well-aligned knee. If malalignment (varus/valgus) exists, a corrective osteotomy must be performed concurrently.
- Ligamentous Stability: The knee must be ligamentously stable (ACL/PCL intact or reconstructed).
4. Pre-Operative Preparation
Success in ACI is heavily dependent on the "biological environment" of the knee.
- Imaging: Mandatory MRI/MOCART scoring to assess defect size, depth, and subchondral bone integrity.
- Mechanical Assessment: Full-leg weight-bearing radiographs to rule out mechanical axis deviation.
- Optimization: Patients are often required to engage in pre-habilitation to maximize quadriceps strength and range of motion (ROM) prior to the index procedure.
- Counseling: Patients must understand the prolonged nature of the recovery, which involves significant non-weight-bearing periods.
5. The Procedure: Step-by-Step
Stage I: Arthroscopic Biopsy
- Examination under anesthesia.
- Diagnostic arthroscopy to confirm defect size and cartilage quality.
- Harvesting of 200–300 mg of healthy cartilage from a non-weight-bearing area.
Stage II: Implantation (Open Arthroplasty)
- Debridement: The defect is carefully cleaned of damaged, unstable cartilage until a stable "vertical wall" of healthy tissue is reached.
- Preparation: The subchondral bone is protected; the goal is to avoid penetrating the bone (unlike microfracture).
- Membrane/Cell Delivery:
- In MACI, the collagen membrane is cut to the exact size of the defect and fixed using fibrin glue.
- In Traditional ACI, a periosteal flap is sutured over the defect and sealed with fibrin glue, followed by the injection of the cell suspension.
6. Post-Operative Recovery Protocol
The rehabilitation process is divided into phases to protect the maturing graft.
| Phase | Timeline | Focus |
|---|---|---|
| Phase I | Weeks 0–6 | Protected weight-bearing (toe-touch), ROM exercises (CPM often used). |
| Phase II | Weeks 6–12 | Gradual weight-bearing progression, focus on quadriceps activation. |
| Phase III | Months 3–6 | Closed-chain strengthening, proprioception, gait correction. |
| Phase IV | Months 6–12 | Return to sport-specific drills, impact loading, high-level agility. |
7. Risks, Complications, and Contraindications
Potential Complications
- Graft Hypertrophy: Overgrowth of the graft, which may require arthroscopic debridement.
- Arthrofibrosis: Excessive scarring leading to limited ROM.
- Delamination: Failure of the graft to integrate with the surrounding cartilage.
- Hardware/Suture Irritation: Localized pain from fixation materials.
Contraindications
- Advanced tricompartmental osteoarthritis (Kellgren-Lawrence Grade III/IV).
- Inflammatory arthropathies (Rheumatoid Arthritis).
- Morbid obesity (BMI >35).
- Active infection.
- Uncorrected mechanical malalignment.
8. Alternative Treatments
When ACI is not suitable, clinicians may consider:
* Microfracture (MFX): Marrow stimulation; cheaper but produces fibrocartilage.
* Osteochondral Allograft Transplantation (OATS): Transfer of bone and cartilage plugs from a donor.
* Osteotomy: Realignment procedures (HTO/DFO) to offload the damaged compartment.
* Total Knee Arthroplasty (TKA): Reserved for end-stage, irreversible joint degeneration.
9. Massive FAQ Section
1. What is the success rate of ACI?
Success rates for ACI in appropriately selected patients are generally reported between 75% and 90% at 5–10 years post-operatively.
2. Is ACI considered experimental?
No. Modern ACI (such as MACI) is FDA-approved and backed by extensive clinical data, though it remains a specialized, high-cost procedure.
3. How long does the surgery take?
The implantation stage typically lasts 90 to 120 minutes, depending on the size and complexity of the lesion.
4. Can ACI treat osteoarthritis?
Generally, no. ACI is designed for focal defects. If the entire joint is degenerated, ACI is unlikely to be successful.
5. Why can't I walk immediately after surgery?
The graft requires a period of "settling" to integrate with the subchondral bone. Immediate weight-bearing can cause the graft to shift or fail.
6. Will I need physical therapy?
Yes, extensive physical therapy is mandatory and is the most significant factor in long-term graft success.
7. What is the difference between ACI and MACI?
MACI is the modern iteration where cells are seeded onto a collagen membrane in the lab, eliminating the need for a periosteal flap harvest from the patient's tibia, which reduces morbidity.
8. Can I return to high-impact sports?
Many patients return to high-impact activities, but this is highly individual and depends on the location of the lesion and the quality of rehabilitation.
9. What is "MOCART" scoring?
It is the Magnetic Resonance Observation of Cartilage Repair Tissue; a standardized way for radiologists to score the quality of the repair tissue on an MRI.
10. Does insurance cover ACI?
Most insurance providers cover ACI, but it typically requires a rigorous "Prior Authorization" process, proving that conservative treatments have failed and that the patient meets specific clinical criteria.
10. Clinical Summary and Outlook
Autologous Chondrocyte Implantation remains the gold standard for biological cartilage repair in young, active patients with focal defects. While the recovery is demanding and the procedure requires significant surgical expertise, the ability to regenerate hyaline-like tissue offers a unique opportunity to delay or prevent the onset of secondary osteoarthritis. Future trends in ACI include the use of 3D-printed scaffolds and potential "off-the-shelf" allogeneic chondrocytes to streamline the two-stage process.
Disclaimer: This guide is for educational purposes for medical professionals and patients. It does not replace the advice of a board-certified orthopedic surgeon. Clinical decisions must be individualized based on patient anatomy, pathology, and surgical history.